Navigation Links
Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
Date:1/22/2008

sumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics' recent press releases are available through the Company's website at http://www.lorusthera.com. For Lorus' regulatory filings on SEDAR, please go to Sedar.com. For SEDAR filings prior to July 10, 2007 you will find these under the company profile for 4325231 Canada Inc.


'/>"/>
SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- Intarcia Therapeutics, Inc. today announced the ... the cost and predictability of non-adherence in type 2 ... of the European Association for the Study of Diabetes ... , Ph.D., of Analysis Group, Inc. presented data from ... studies to characterize the prevalence of non-adherence and serial ...
(Date:9/17/2014)... , Sept. 17, 2014 RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today announced that it has been granted a ... Office on its unique delivery system for delivering ... phagocytic cells for the treatment of diseases with ...
(Date:9/17/2014)... MESSENGER has just celebrated its 10 year anniversary in ... of its latch valves, V27200-818, operating onboard this spacecraft. ... the planet Mercury. It is only the second spacecraft ... vast amount of information and images of the planet. ... that also include permanent magnets to maintain the valve ...
(Date:9/16/2014)... that can harvest energy from jaw movements has been ... It is hoped that the device can generate electricity ... of small-scale implantable or wearable electronic devices, such as ... devices. , The first results of the device,s performance ... journal Smart Materials and Structures . , Jaw ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4'Smart material' chin strap harvests energy from chewing 2
... pioneer in scalable, high performance cell loading systems, ... with industry experts on the,challenges in developing cell-based ... to the industry and will be held by ... of the respected industry experts leading this live ...
... Issues and Recommendations, BETHLEHEM, Pa., Nov. ... Clinical Value Marketing, Infusion Systems Division and ... for B. Braun Medical,Inc. (B. Braun), a ... services,recently represented B. Braun at the Institute ...
... CITY, Nov. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... company focused on,endocrine therapy and oncology, will announce ... Thursday, November 13, 2008 at 7:30 a.m.,The Company ... discuss these,results later that same day at 10:00 ...
Cached Biology Technology:MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery 2B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit 2B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit 3
(Date:9/16/2014)... are responsible for practically all vital functions in ... forward signals, transport particular substances and control immune ... proteins do not function independently of each other, ... examine the protein networks, you find many similarities ... from TUM,s Chair of Plant Systems Biology. "Some ...
(Date:9/16/2014)... Fla. , Sept. 16, 2014  Cross ... identity management solutions, announced today the launch of ... to authenticate the identity of an individual using ... Android-based Verifier Sentry rapidly reads credential documents with ... ID by matching the biometric to a live ...
(Date:9/16/2014)... of wild foods, autumn harks a season of bounty. ... luring intrepid collectors to woodlands in search of elusive ... in the allure of the treasure hunt, and their ... existence. But are the mushrooms which you are eating ... diverse yet vastly underdocumented although some estimates range ...
Breaking Biology News(10 mins):Good networkers make prime targets 2Cross Match Launches New Identity Management Handheld Solution 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 3
... by children with neurofibromatosis type 1 (NF1), a genetic ... in improved cognitive function, according to a study in ... Characteristics of NF1 (incidence 1:3,000) include skin disorders, problems ... the frequent occurrence of cognitive disabilities, such as visual-spatial ...
... LAFAYETTE, Ind. - According to a new study, ... snowmelt in the western United States than was ... new water management challenges for agriculture, ecosystems and ... professor of earth and atmospheric sciences, discovered that ...
... at Cold Spring Harbor Laboratory (CSHL) are part of ... of an enzyme in the brain can reduce telltale ... CSHL Professor Yi Zhong, Ph.D., whose lab studies genetic ... of transgenic fruit flies that was central in the ...
Cached Biology News:Statin does not appear helpful for children with learning disabilities caused by genetic disorder 2Study: Future snowmelt in West twice as early as expected; threatens ecosystems and water reserves 2Study: Future snowmelt in West twice as early as expected; threatens ecosystems and water reserves 3Scientists demonstrate means of reducing Alzheimer's-like plaques in fly brain 2
Request Info...
Imject Freund's Complete Adjuvant (FCA)...
... cytoplasmic granules, is a key step ... (e.g. basophils, neutrophils, eosinophils, and mast ... secretory granules contain many proinflammatory mediators ... proteases (Hallgren, 2001). Tryptase, a tetrameric ...
... Safe DNA gel stain was developed specifically for ... bromide for staining DNA in agarose or acrylamide ... mutagenic than ethidium bromide but SYBR Safe stain's ... bromide. SYBR Safe stain comes as a premixed ...
Biology Products: